ArticleProbiotics and antimicrobial proteins2026
Dietary Supplementation with Recombinant Bacillus subtilis Expressing Insulin-Like Growth Factor 1a (IGF1a) Promotes Muscle Hypertrophy in Zebrafish (Danio rerio).
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Aquaculture is a key sector for animal protein production that has shown significant growth, which can be further improved in terms of carcass yield and fillet quality. Enhancing skeletal muscle growth in fish through biotechnological strategies is a promising alternative with substantial commercial application potential. Fish growth regulation occurs via the somatotropic axis, where Insulin-Like Growth Factor 1 (IGF1) plays a critical role in skeletal muscle hyperplasia and hypertrophy. In this study, a strain of the probiotic bacterium Bacillus subtilis was genetically modified to express zebrafish (Danio rerio) IGF1a, which was used as a dietary supplement for zebrafish. The experiment lasted 60 days, during which zootechnical performance, muscle morphometry, and the gene expression of the IGF system, as well as muscle development genes, were evaluated. The results demonstrated that supplementation with the genetically modified probiotic improved zootechnical performance and induced muscle hypertrophy in the fish. Additionally, it promoted the induction of IGF1Rb receptor and Myf5 expression in skeletal muscle. These findings suggest that IGF1a produced and secreted by B. subtilis in the zebrafish intestine was able to trigger an endocrine action, interacting with the IGF1Rb receptor in the muscle and promoting hypertrophy. The results provide evidence of the potential of B. subtilis as a biofactory for growth factors capable of impacting the host and inducing tissue-specific growth, which could enhance carcass yield in fish used in commercial aquaculture.
Indexed as
Identifiers
40653538What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.